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Objectives: The objectives were to compare the long-term outcomes, including hysterectomy, chronic pelvic pain
(CPP) and abnormal uterine bleeding (AUB), in women post hysteroscopic sterilization (HS) and laparoscopic
tubal ligation (TL) in the Medicaid population.
Study design: This was a retrospective observational cohort analysis using data from the US Medicaid Analytic
Extracts Encounters database. Women aged 18 to 49 years with at least one claim for HS ( =3929) or TL ( =n n
10,8 75) betw een Ju ly 1, 200 9, thro ugh Dec embe r 31, 2010 , were in clud ed. Mai n outco me measu res we re
 
 
hysterectomy, CPP or AUB in the 24 months poststerilization. Propensity score matching was used to control
for patient demographics and baseline char acteristics. Logistic regression analysis investig ated the variables
associated with a 24-month rate of each outcome in the HS versus laparoscopic TL cohorts.
Results: Postmatching analyses were performed at 6, 12 and 24 months post index procedure. At 24 months,
hysterectomy was more common in the laparoscopic TL than the HS group (3.5% vs. 2.1%; p=.0023), as was
 
 
diagnosis of CPP (26.8% vs. 23.5%; p=.0050). No significant differences in AUB diagnoses were observed. Logistic
 
 
regr essi on ide nti ed HS a s bei ng ass ocia ted wi th low er ri sk of h yste recto my ( od ds ra tio [OR] 0 .77 [ 95%fi
 
 
confidence interval {CI} 0.60–0.97]; p=.0274) and lower risk of CPP diagnosis (OR 0.91 [95% CI 0.83–0.99]; p=
 
 
.0336) at 24 months poststerilization.
Conclusion: In Medicaid patients, HS is associated with a significantly lower risk of hysterectomy or CPP diagnosis
 
 
 
 
 
 
 
 
 
 
2 4 m o n t h s p o s t s t e r i l i z a t i o n v e r s u s l a p a r o s c o p i c T L . I n c i d e n c e o f A U B p o s t s t e r i l i z a t i o n i s n o t s i g n ific a n tl y
different. While some differences in outcomes were statistically signi cant, the effect sizes were small, and thefi
conclusion is one of equivalence and not clinical superiority.
Implications statement: This propensity score matching analysis confirms that pelvic pain and AUB are common in
 
 
 
 
women before and after sterilization regardless of whether the procedure is perform ed hysteroscopically or
laparoscopically. Moreover, HS is associated with a signi cantly lower risk of hysterectomy or a CPP diagnosisfi
 
 
 
 
in the 24 months poststerilization when compared to TL.
© 2018 Elsevier Inc. All rights reserved.
Keywords :
Hysteroscopic sterilization
Laparoscopic tubal ligation
 
 
Abnormal uterine bleeding
Chronic pelvic pain
Hysterectomy
1. Introduction
Although trends suggest a declining rate of female sterilization in the
 
 
United States , it remains the second most common form of contra-[1]
ceptio n am ong US reproduc tive-ag ed women . Me thods avai lable[ 2 ]
for interval sterilization (sterilization at a time remote from delivery)
include laparoscopic tubal ligation (TL) and hysteroscopic sterilization
(HS). TL requires entry into the peritoneal cavity and general anesthesia,
whereas HS involves an implant being placed into the fallopian tubes
through a hysteroscope.
 
 
In an analysis of a large commercial insurance database, women who
underwent HS had a higher rate of menstrual dysfunction but a lower
rate of hysterectomy and pelvic pain 1 to 5 years postprocedure com-
 
 
 
 
pared to women who had lapa rosc opic TL [ 3 ] . Ano th er s tu dy of th e
 
 
same d ataba se s howed th at during a 12 -mon th foll ow-up, women
who underw ent HS versus T L ha d th e s ame incid ence of opio id-
managed pelvic pain [4]. Finally, while not comparative, a retrospective
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(chronic headache, low back pain, pelvic pain, and bromyalgia) are 6fi
times as likely to experience both acute and chronic pelvic pain (CPP)
following the Essure hysteroscopic tubal sterilization procedure .[5]
Women with no or public insurance are more likely to undergo ster-
 
 
iliz ati on th an wom en wit h com mercia l in surance. Afri can Am eric an
 
 
race, less education and poverty also increase the likelihood of steriliza-
tion . Cu rrent data on seque la e a fter ster ilizati on are limited to[1,6]
 
 
 
 
women with c ommerc ial insu rance , and it is unkn own wheth er[ 3 ]
the sa me out comes c an be ex pecte d in a popula tion of women who
are publicly insured.
The current study was undertaken to compare the rate of hysterec-
 
 
 
 
tomy and the diagnosis of CPP or abnormal uterine bleeding (AUB), out-
comes a lso explore d by Perk ins et al., i n the 2 4 mon ths after s terilization
 
 
by laparoscopic TL or HS in women who were covered by Medicaid.
2. Materials and methods
2.1. Data source
 
 
 
 
This retrospective, observational cohort study used data from the US
Medicaid Analytic Extracts (MAX) Encounters database, which contains
individual-level information on characteristics of Medicaid enrollees.
 
 
 
 
This database includes demographic data (e.g., age, race), information
on dispe nsed pres crip tion dr ugs iden ti ed by a Na tiona l Drug Cod e,fi
Medicaid services (e.g. physician services, laboratory/x-ray, clinical ser-
 
 
vices , premi um p aymen ts, ou tpati ent h ospita l cla ims), inst ituti onal
long- term care se rvic es and inpa tient s ervices (includ ing dia gn oses ,
procedures, discharge status, length of stay and payment amount). In
compliance with the Health Insurance Portability and Accountabilit y
Act of 1996, the database comprises fully deidentified data sets. There-
fore, this study was exempt from Institutional Review Board overview
 
 
under the Common Rule (45 CFR x46.101(b) [4]).
2.2. Subjects
Women aged 18 to 49 years who had at least one claim for HS (Cur-
 
 
rent Procedural Terminology [CPT] code: 58565) or interval laparoscop-
ic TL ( CP T cod es: 586 70 or 586 71) a t any t ime dur ing July 1, 2 009,
through December 31, 2010 (Supplementary Fig. 1), were included in
this study. The date of the claim for the sterilization procedure was de-
fined as th e in dex date. The st udy include d on ly women wh o h ad
6 mo nths of contin uous medic al and ph arma cy cl aims data prio r to
the procedure and at least 24 months after the procedure. The entire
 
 
study period, including baseline an d foll ow-up, was January 1, 200 9,
throug h D ecemb er 3 1, 2012. At the ti me of th e a nalys is, 35 s tates
were av ailable in t he 20 12 MAX dat a.
 
 
Patients were excluded from the analysis if they underwent postpar-
 
 
tum TL during the study period; had already undergone a sterilization
procedure during the baseline period; had a claim for pregnancy or de-
 
 
livery within 6 weeks before the index date; had more than one type of
sterilization procedure on the index date; had concurrent procedures on
the same day as the index sterilization procedure that may have an im-
  
 
pact on the study outcomes (Supplementary Table 1); or had a modifier
-53 next to the procedure code on the index date, indicating an incom-
plete procedure.
All available data that met the inclusion and exclusion criteria were
included.
2.3. Analysis and outcomes
(ICD-9 ) di agnos tic codes f or pe lvic pa in/low er ab domin al pain and
AUB (Supplementary Table 2).
Poststerilization CPP was defined as receiving ≥2 diagnoses of pelvic
pain/ lower abdomin al pain on at least 2 se para te vi sit s, beg inning
 
 
2 weeks post index procedure. At least one of these diagnoses had to
 
 
be receive d at least 3 month s after the inde x proced ure (ind icati ng
 
 
 
 
 
 
some degr ee of chronicity). AUB was de ned as 2 diagnos es of AUBfi ≥
at least 2 weeks post index procedure with at least one of them occur-
 
 
 
 
ring beyond 3 months after the index procedure.
2.4. Statistical analysis
 
 
All baseline and outcome variables were analyzed descriptively. Per-
centages and numbers were calculated for dichotomous and polychoto-
mous variables, and compared using chi-square test with p values and
95% confidence intervals (CIs). Means with SDs were calculated for con-
 
 
 
 
tinuous variables and compared using tests, with p values and 95% CI.t
In addition, standardized differences (effect size [ES]), de ned as the ab-fi
 
 
solute difference in sample means divided by an estimate of the pooled
SD of the variable, were calculated for each variable. Standardized dif-
ferences were reported as 100 times the absolute ES difference.
Patient matching was carried out in two steps by the combination of
 
 
exact match of patient characteristics and propensity score matching
(PSM). Exact patient match ensured that the matched patient groups
 
 
have the same distribution of key baseline patient characteristics (as
identified by DeNoble et al. in their study of medical comorbidities com-
 
 
mon in reproductive aged women), and included baseline pain status
 
 
(as identified by Yunker et al. in their study of pelvic pain post Essure
 
 
placement) and the presence of baseline AUB diagnosis codes [5,7]. His-
 
 
tory of pain was not included in the propensity score as it would provide
 
 
a good match rather than an exact match. Baseline pain and baseline
AUB are cons idered s tr ong con fo unders t hat are impo rtant to be
matched exactly [5,7]. PSM was then conducted within each of the strat-
i ed groups, and additional patient demographic and clinical character-fi
 
 
istics were controlled in the PSM that enabled the matched populations
 
 
to have the same and/or similar baseline characteristics. Multivariable
logistic re gression ana lysis was carried ou t on the entir e unmatched
 
 
sample as a sensitivity analysis to check on the robustness of the nd-fi
 
 
ings from the matching analysis. Multivariable logistic regression was
 
 
used to generate the propensity score, with women having HS versus
laparos cop ic TL as th e depen dent vari able, and the c ovari ates in th e
PSM inc luded a ge (18 2 4 [refe renc e], 25 34, 35 44,– – 2 9 , 3 0 – –3 9 , 4 0 –
45 49 ); race ( White [ refe rence] , Afri can Amer ican, H ispan ic, ot h er–
 
 
race, unknown); Charlson Comorbidity Index (CCI) score (0 [reference]
or 1); geogra phic re gion ( North East [ref erenc e], So uth, Mi dwest ,≥
West, other); c omorbidities (hyperten sion, asthma, hypothyroidism,
 
 
diabetes, obesity); pelvic pain-related conditions ( broid, benign ovar-fi
ian neoplasms); prior pregnancy/delivery (during the 6-month baseline
but beyond 6 weeks prior to the index date); and oral contraceptive or
injectable methods used during a 6-month baseline prior to index. Lo-
gistic regressions were also conducted using the unmatched population
to compare the risk of hysterectomy, CPP and AUB 24 months post-HS
versus laparoscopic TL by controlling patient demographic and clinical
 
 
 
 
characteristics. All statistical analyses were carried out using SAS 9.3.
3. Re sults
3.1. Patient characteristics
Overall, 14,804 women met the inclusion criteria and had at least
24 months of continuous data poststerilization; 3929 had undergone
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The p rimary outc omes measure s we re t he pro portio n of women
who underwent hysterectomy and were diagnosed with CPP or diag-
nosed with AUB at 6, 12 and 24 months post index event. Hysterectomy
was identi ed based on CPT codes, and the latter two outcomes werefi
 
 
ident i ed usingfi Int ernati o nal Classi cati on of Disease s, Ninth Revis ionfi
24 months of continuous data poststerilization; 3929 had undergone
HS, and 10,875 had undergone laparoscopic TL (Supplementary Fig. 2
and ). At baseline, women in the HS cohort were older than inTable 1
 
 
the la parosc opic TL cohor t (mea n [SD ] age 31.8 [ 6.1] vs . 30 .4 [5 .9]
years , re spect ivel y; p .00 01). Fewe r women in the laparo scopic TLb
 
 
than in the HS group had diagnosis codes for hypertension (10.2% vs.
7.7%; p .0001), diabetes (5.1% vs. 3.5%; pb b.0001) or obesity (6.6% vs. 4.7%;
pb.0001 ). Fewer women in the HS group than those in the laparoscopic TL
group received a diagnosis code for a pain condition (chronic headache,
low back pain, pelvic pain, fibromyalgia) (35.1% vs. 40.0%; pb.0001). Base-
 
 
line AUB was higher in the HS group than in the laparoscopic TL group
(8.1% vs. 6.4%; p=.0004). Fewer women in the HS group used no pre-
scription contraceptive during the baseline period (no contraceptive
use: 63.7 % vs. 83.7%; pb.0001 ). The differen ce in contraceptive u se was
most marked for oral contraceptives (8.8% in the HS group vs. 5.3% in
the laparoscopic TL group; pb.0001) a nd for injectables ( 25.1% in the H S
group vs. 7.5% in the laparoscopic TL group; pb.0001). There were also sig-
ni cant diffe rences in race/ethnicity, as shown infi Table 1. PSM adjusted
baseline characteristics were similar between both groups except for in-
flammato ry bowel disease and low back pain.
 
 
Table 1
 
 
Baseline demographics in the overall study population and the PSM adjusted population a.
Overall study population PSM adjusted population
HS
(n=3929)
Laparoscopic TL
(n=10,875)
p value 95%CI for
difference
Effect
size
HS
(n=2673)
Laparoscopic TL
(n=2673)
p value 95%CI for
difference
Effect
size
Mean (SD) age, years 31.8 (6.1) 30.4 (5.9) 1.62, 1.18 30.9 (5.6) 30.8 (5.7) .3414 0.45, 0.16 2.60b.0001 − − 23.38 − −
Age group, (%)n
18 20 years 3 (0.1) 8 (0.1) .9561 0.10, 0.10 0.10 2 (0.1) 1 (0.04) .5636 0.09, 0.16 1.58– − −
21 24 years 447 (11.4) 1818 (16.7) 6.56, 4.12 328 (12.3) 334 (12.5) .8033 1.99, 1.54 0.68– b.0001 − − 15.41 −
 
 
25 29 years 1117 (28.4) 3571 (32.8) 6.07, 2.74 9.57 886 (33.2) 884 (33.1) .9536 2.45, 2.60 0.16– b.0001 − − −
 
 
30 34 years 1107 (28.2) 2865 (26.3) .0265 0.20, 3.46 4.11 762 (28.5) 757 (28.3) .8795 2.23, 2.61 0.41– −
35 39 years 775 (19.7) 1658 (15.3) 3.06, 5.90 467 (17.5) 468 (17.5) .9713 2.07, 2.00 0.10– b.0001 11.81 −
40 44 years 369 (9.4) 783 (7.2) 1.16, 3.23 7.95 200 (7.5) 200 (7.5) 1.0000 1.41, 1.41 0.00– b.0001 −
 
 
45 49 years 111 (2.8) 172 (1.6) 0.67, 1.81 8.48 28 (1.1) 29 (1.1) .8941 0.59, 0.51 0.36– b.0001 −
Race
White 2076 (52.8) 6959 (64.0) b.0001 − − −10.97, 7.34 1603 (60.0) 1599 (60.0) .911118.52 2.48, 2.78 0.31
African American 1152 (29.3) 2225 (20.5) 7.57, 10.78 686 (25.7) 693 (25.9) .8268 2.61, 2.08 0.60b.0001 21.48 −
Hispanic 496 (12.6) 1160 (10.7) .4316 1.05, 0.44 1.47 293 (11.0) 293 (11.0) 1.0000 1.67, 1.67 0.00− −
Other race 96 (2.4) 182 (1.7) 0.45, 1.51 7.10 36 (1.4) 35 (1.3) .9049 0.58, 0.65 0.33b.0001 −
Unknown 109 (2.8) 349 (3.2) .2706 1.92, 0.53 2.06 55 (2.1) 53 (2.0) .8458 0.68, 0.83 0.53− −
CCI score, (%)n
 
 
0 3313 (84.3) 9252 (85.1) .2581 2.07, 0.57 2.09 2474 (92.6) 2477 (92.7) .8754 1.51, 1.29 0.43− −
 
 
 
 
1 2 558 (14.2) 1509 (13.9) .6131 0.94, 1.60 0.94 188 (7.0) 185 (6.9) .8721 1.25, 1.48 0.44– − −
3 4 34 (0.9) 68 (0.6) .1190 0.09, 0.57 2.79 6 (0.2) 5 (0.2) .7628 0.21, 0.28 0.83– − − 
N4 24 (0.6) 46 (0.4) .1413 0.08, 0.46 2.62 5 (0.2) 6 (0.2) .7628 0.28, 0.21 0.83− −
Comorbidities, (%)n
Hypertension 402 (10.2) 841 (7.7) 1.43, 3.57 8.74 111 (4.2) 116 (4.3) .7345 1.27, 0.89 0.93b.0001 −
 
 
Asthma 246 (6.3) 758 (7.0) .1298 1.61, 0.19 2.85 97 (3.6) 99 (3.7) .8843 1.08, 0.93 0.40− −
Hypothyroidism 140 (3.6) 348 (3.2) .2744 0.30, 1.03 2.01 39 (1.5) 37 (1.4) .8173 0.56, 0.71 0.63− −
 
 
Diabetes 202 (5.1) 379 (3.5) 0.88, 2.43 8.16 47 (1.8) 50 (1.9) .7585 0.83, 0.60 0.84b.0001 −
 
 
Obesity 258 (6.6) 511 (4.7) 1.00, 2.74 8.11 65 (2.4) 66 (2.5) .9295 0.87, 0.79 0.24b.0001 −
Rheumatoid arthritis 21 (0.5) 47 (0.4) .4163 0.16, 0.36 1.47 9 (0.3) 3 (0.1) .0829 0.03, 0.48 4.74− −
 
 
IBD 19 (0.5) 34 (0.3) .1241 0.07, 0.41 2.71 14 (0.5) 5 (0.2) 0.02, 0.66 5.66− .0386
SLE 14 (0.4) 35 (0.3) .7470 0.18, 0.25 0.59 0 (0.0) 2 (0.1) .1572 0.18, 0.03 3.87− −
Comorbidities associated with pelvic pain, (%)n
Fibroid 67 (1.7) 125 (1.2) 0.10, 1.01 4.69 4 (0.2) 5 (0.2) .7387 0.26, 0.18 0.91.0083 −
Benign ovarian neoplasm 140 (3.6) 420 (3.9) .4001 0.98, 0.38 1.58 44 (1.7) 44 (1.7) 1.0000 0.68, 0.68 0.00− −
Endometriosis 19 (0.5) 84 (0.8) .0619 0.56, 0.02 3.66 10 (0.4) 11 (0.4) .8269 0.37, 0.30 0.60− − −
Prolapse 13 (0.3) 51 (0.5) .2581 0.36, 0.08 2.19 9 (0.3) 9 (0.3) 1.0000 0.31, 0.31 0.00− −
Preexisting pain during baseline period, (%)n
 
 
Pelvic pain 880 (22.4) 2792 (25.7) 4.82, 1.74 7.67 522 (19.5) 505 (18.9) .5551 1.48, 2.75 1.61b.0001 − − −
 
 
Low back pain 485 (12.3) 1772 (16.3) 5.19, 2.71 294 (11.0) 344 (12.9) 3.61, 0.13 5.77b.0001 − − 11.29 .0349 − −
Chronic headache 301 (7.7) 1014 (9.3) 2.66, 0.67 5.97 185 (6.9) 187 (7.0) .9144 1.44, 1.29 0.29.0017 − − −
Fibromyalgia 82 (2.1) 248 (2.3) .4815 0.72, 0.33 1.32 42 (1.6) 42 (1.6) 1.0000 0.67, 0.67 0.00− −
 
 
Any form of pre-existing pain b 1378 (35.1) 4353 (40.0) 6.71, 3.20 830 (31.1) 830 (31.1) 1.0000 2.48, 2.48 0.00b.0001 − − 10.24 −
 
 
AUB, (%)n 317 (8.1) 695 (6.4) 0.71, 2.65 6.48 101 (3.8) 101 (3.8) 1.0000 1.02, 1.02 0.00.0004 −
Prior pregnancy or delivery, c n (%) 1692 (43.1) 4793 (44.1) .2745 2.82, 0.80 2.04 1159 (41.9) 1154 (41.9) .8902 2.47, 2.84 0.38− −
Contraceptives used during baseline period, d n (%)
 
 
None 2502 (63.7) 9097 (83.7) 21.63, 18.31 2042 (76.4) 2043 (76.4) .9743 2.31, 2.24 0.09b.0001 − − 46.55 −
 
 
Oral contracepti ve 347 (8.8) 572 (5.3) 2.59, 4.55 145 (5.4) 145 (5.4) 1.0000 1.21, 1.21 0.00b.0001 13.99 −
 
 
Contraceptive patch 45 (1.2) 133 (1.2) .7019 0.47, 0.31 0.72 35 (1.3) 35 (1.3) 1.0000 0.61, 0.61 0.00− −
Vaginal ring 106 (2.7) 221 (2.0) 0.09, 1.24 4.38 75 (2.8) 63 (2.4) .3007 0.40, 1.30 2.83.0150 −
Implant 0 (0.0) 9 (0.1) .0713 0.14, 0.03 4.07 0 (0.0) 1 (0.04) .3173 0.11, 0.04 2.74− − −
Intrauterine system 21(0.5) 71 (0.7) .4183 0.39, 0.16 1.54 15 (0.6) 20 (0.8) .3965 0.62, 0.25 2.32− −
 
 
 
 
 
 
Injectable 987 (25.1) 813 (7.5) 16.20, 19.09 378 (14.1) 376 (14.1) .9374 1.79, 1.94 0.21b.0001 49.19 −
 
 
 
 
Note: Values in italics indicate those meeting the criteria for statistical (p value).
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Note: Values in italics indicate those meeting the criteria for statistical (p value).
 
 
IBD, in ammatory bowel disease; SLE, systemic lupus erythematosus.fl
a  
 
 
 
Only 35 states available in the 2012 MAX data at time of analysis: AK, AL, AR, CT, DE, FL, GA, IA, IL, IN, KY, MD, MI, MN, MO, MS, MT, NC, NE, NJ, NV, NY, OH, OK, OR, PA , SC, S D, T N, TX , V A,
VT, WA, WV and WY.
b Included pelvic pain, low back pain, chronic headache or bromyalgia.fi
c Six weeks or more before index date.
d
 
 
Within the 6 months prior to the index date.
3.2. Contraceptive use in the overall study population
 
 
“ ”No use of prescription contraceptives poststerilization (2 weeks
 
 
 
 
preindex to 3 months postindex) was significantly higher in the laparo-
scopic TL group compared to the HS group (97.0% vs. 77.2%; p .0001, re-b
spectively) . The differ ence in c ontrac eptive use poststeriliz ation was
most marked for oral contra cepti ves (HS, 6.4% vs. laparos copic TL,
1.5%; p .0001 ) and fo r injec table s (HS, 14 .5% vs . lapa roscop ic TLb
group, 0. 8%; pb.0001).
3.3. Overall population
In a n unmatched a nalysis, posts terilization hystere ctomy and a diag-
 
 
nosis of CPP after sterilization were signi cantly more common in thefi
laparos cop ic TL group t han the HS gr oup bot h at 12 mont hs and
 
 
 
 
24 months (p .005 for all) ( ). The rates of AUB diagnoses afterb Table 2
sterili zati on procedu re we re signi c antly more common in th e H Sfi
group than the laparoscopic TL group at 12 months (p=.0059) but not
at 24 months (p=.3145) (Table 2).
3.4. Postmatching analysis
At 6 months, there were no significant differences between the lap-
aroscopi c TL gro up and the HS gro up in the rates of poststeri lizati on
hysterectomy, diagnosis of CPP or diagnosis of AUB (Table 3). Hysterec-
 
 
tomy was significantly more common in the laparoscopic TL group than
 
 
 
 
 
 
 
 
the HS group at 24 months (3.5% vs. 2.1%; p=.0023). A diagnosis of CPP
after sterilization was significantly more common in the laparoscopic TL
group than the HS group at 12 months (13.8% vs. 11.7%; p=.0215) and
24 months (26.8% vs. 23.5%; p=.0050). There were no significant differ-
ences in the rates of AUB diagno ses after ster iliz ation proc edure at
 
 
12 months (p=.4334) and 24 months (p=.7629).
3.5. Logistic regression analysis
Logistic regres sio n ide nti ed HS as be ing associated with a lowe rfi
risk of hyste recto my (od ds ratio [OR ] 0. 7 7 [95% CI 0. 60–0 . 9 7 ] ; p =
.0274 ) or a CPP d iagnos is (OR 0.91 [95% CI 0.8 3 0.99 ]; p= .0336) in–
 
 
the 24 months poststerilization; there was a similar risk of AUB com-
pared t o laparos copic T L (Table 4).
4. Discussion
 
 
Both un matched and PSM a nalyse s of Med icaid pa tien ts ind icate
 
 
that pelvic pain and AUB are common in women before and after steril-
izati on whether the proc edure is pe rfor med hyst erosc opical ly or
laparoscopically. Moreover, HS is associated with a significantly lower
risk of hyste recto my a t 2 4 mon ths or a CP P di agnos is at 12 a nd
24 months poststerilization when compared to TL, consistent with ear-
lier repo rts [3]. Higher rates of AUB were found in the unmatched com-
pariso n at 6 and 12 months bu t n ot at 2 4 m onth s; th ere were no
differences in AUB at any time point in the matched analysis.
Consistent with previous reports [8], the publicly insured wom en in
 
 
our study underwent sterilization at an average age of about 30 years
compared to a mean age of about 37 years for commerci ally insu re d
 
 
women. [3,8]. Consistent with our data, a comparison of Medicaid and
commercially insured women undergoing HS or TL found that the Med-
 
 
icaid cohort was more likely to be using an injectable contraceptive and
less li kely to be usi ng an oral c ontrac eptive prior to ste rili zation .[ 8 ]
 
 
 
 
Medicaid patients had a higher mean CCI score and were more likely
to be obese or to have asthma than commercially insured women but
less likely to have hypothyroidism [8].
Previous r esearchers found a significant differenc e in t he rate of AUB
 
 
during the first year following HS versus TL [3]. This potentiall y may be
explained by the need to continue contraception after HS until a confir-
mation test has demonstrated proper insert location. Therefore, in the
first several months after HS, women are still experiencing the effects of
 
 
taking, then withdrawing from, hormonal contraception, whereas
women undergo ing TL can cease usi ng contrace ptives imme diately after
sterilization. In our mat ched analysis, however, the rate of AUB w as sim-
ilar at 6, 12 and 24 mon ths postprocedure (Table 3). Logistic regression
analysis in our study cohort identi ed baseline obesity, race (Africanfi
American, Hispanic, other), pain conditio n, AUB and the use of injectable
contraceptives as risk factors for an AUB diagnosi s after ste rilization.
Reports have emerged about pain developing after HS [5,9,10], but
until r ecently, t he studies comparing outcomes after HS and TL w ere lim-
ited by their definit ions of pain (e.g., severe pain requiring opioids) [4] or
by their s hort durat ion of follow-up [11]. In using a definition of pain that
was consisten t with previo us research [3], we found a h igher rate of CPP
diagnosis after sterilization in pati ents who u nderwent TL compared with
those who underwent HS (26.8% vs. 23.5%). While the rate of CPP was sig-
nificantly higher in the TL versus the HS g roup in this study, the difference
is small and unlikely to represent a clinically important difference. Ne ver-
theless, the data from this study are consistent with Perkins et al. in that
HS is not associated with more CPP than is TL [3].
These data are an important adjunct to previous database analyses,
 
 
which have used data from employer-based insurance plans and ex-[3]
clude d Me di caid or Medic are patien ts. Accor ding to the Women' s
Table 2
 
 
Descriptive outcomes of women in the TL cohort and HS cohort during the 24-months
follow-up period (unmatched)
HS
( =3929)N
n (%)
Laparoscopic
TL ( =10,875)N
n (%)
p value 95% CI for
difference
Effect
size
6-Month outcomes
Hysterectomy 17 (0.4) 77 (0.7) .0625 0.53, 0.02 3.66− −
Chronic pelvic pain 215 (5.5) 737 (6.8) 2.16, 0.45 5.44.0043 − −
 
 
AUB 88 (2.2) 131 (1.2) 0.53,1.54 7.96b.0001
12-Month outcomes
Hysterectomy 39 (1.0) 190 (1.8) 1.15, 0.36 6.49.0010 − −
Chronic pelvic pain 517 (13.2) 1789 (16.5) 4.56, 2.03 9.28b.0001 − −
AUB 189 (4.8) 413 (3.8) 0.25,1.77 4.99.0059
24-Month outcomes
Table 3
PSM adjusted descriptive outcomes of women in the TL cohort and HS cohort during the
24-months follow-up period
HS
( =2673)N
n (%)
Laparoscopic
TL ( =2673)N
n (%)
p value 95% CI for
difference
Effect
size
6-Month outcomes
 
 
Hysterectomy 10 (0.4) 16 (0.6) .2382 0.60, 0.15 3.23−
 
 
Chronic pelvic pain 127 (4.8) 139 (5.2) .4504 1.61, 0.72 2.06−
AUB 44 (1.7) 40 (1.5) .6600 0.52, 0.82 1.20−
12-Month outcomes
 
 
Hysterectomy 25 (0.9) 36 (1.4) .1566 0.98, 0.16 3.87−
 
 
Chronic pelvic pain 312 (11.7) 368 (13.8) 3.88, 0.31 6.29.0215 − −
AUB 108 (4.04) 97 (3.6) .4334 0.62, 1.44 2.14−
24-Month outcomes
 
 
Hysterectomy 57 (2.1) 94 (3.5) 2.27, 0.50 8.36.0023 − −
 
 
Chronic pelvic pain 628 (23.5) 717 (26.8) 5.65, 1.00 7.68.0050 − −
 
 
AUB 212 (7.9) 218 (8.2) .7629 1.68, 1.23 0.83−
 
 
Note: Val ues in ita lic s i ndic ate tho se meet ing the cri teri a f or stati sti cal sig nific a n c e
(p value).
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clude d Me di caid or Medic are patien ts. Accor ding to the Women' s
 
 
 
 
Health 2013 repo rt, abo ut two thir ds of wo me n aged 1 8 to 64 year s
(67.3%) have private health insurance , while 13.2% rely on public[12]
 
 
insurance. Therefore, although our data set is representative of only a
 
 
small proportion of US women, it is a cohort in whom outcomes after
steriliz ation have not b een previous ly studied in detail.
Hysterectomy 97 (2.5) 382 (3.5) 1.64, 0.45 6.13.0015 − −
Chronic pelvic
pain
 
 
1010 (25.7) 3223 (29.6) 5.54, 2.32 8.79b.0001 − −
 
 
AUB 366 (9.3) 955 (8.8) .3145 0.52,1.59 1.86−
Note: Values in italics indicate those meeting the criteria fo r statistical signi cance (pfi
value).
Database analyses have limitations. The comorbidities and diagnoses
used are b ased solely on ICD-9 or CPT codes, and t here is potential for cod-
ing errors to oc cur during data e ntry. The MAX data base has 2012 data for
only 35 states; however, the data come from all regions of the United
States and are therefore likely to be nationally re presentative. MAX files
contain only Medicaid- paid services and do not capture service use or ex-
penditures during periods of nonenrollment, services paid by other
payers or services provided at no charge. This database c onsists of claims
submitted by healthc are providers to insurance companies for reimburse-
ment on behalf of individuals, probably co ntributing to underrepor ting of
AUB and pelvic pain events as many patients experience these conditions
without consulting a healthcare professional [13,14]. In addition, other
limitations may be associated with claims data use because data are col-
lected for the purpose of payment and not research. Comorbidit ies and di-
agnoses were based solely on ICD-9 or CPT c odes. Operationalization of
 
 
 
 
A strength of our analysis was the exclusion of women who had con-
comitant gynecologic proce dures on the index steril ization date that
could have an impact on the study outcome measures. Because many
 
 
 
 
of these procedures are more likely to be performed in one study cohort
than the other (eg, lysis of adhesions will only be performed in the lap-
 
 
aroscopic group), allowing these additionally treated subjects to remain
 
 
in the an alysi s woul d create an un contro llabl e bias. An add itiona l
strengt h of our a nalysi s is t he use of th e pro pe nsity scor e mod el ,
which included all measured baseline covariates potentially associated
wit h t rea tm en t a ssig nm en t a nd o utc om es .
In conclusion, our data demonstrate that the incidence of hysterec-
 
 
 
 
 
 
tomy and CPP in publicly insured women is lower after HS compared
to aft er TL. In propens ity score m atched analy ses, HS is associa ted
 
 
 
 
 
 
with lower odds of having a hysterectomy at 24 months or receiving a
diagnosis of CPP at 12 and 24 months, but not 6 m onths, a fter steriliza-
 
 
Table 4
Logistic regression analysis examining the OR of having different outcomes at 24 months based on type of sterilization procedure and baseline characteristics.
Hysterectomy Pelvic pain AUB
OR (95%CI) p value OR (95% CI) p value OR (95% CI) p value
Procedure
Laparoscopic TL (ref)
HS 0.77 (0.60, 0.97) 0.91 (0.83, 0.99) 1.06 (0.93, 1.21) .3967.0274 .0336
Age
18 24 years (ref)–
25 29 years 1.17 (0.89, 1.54) .2603 0.76 (0.68, 0.84) 0.93 (0.78, 1.10) .3934– b.0001
30 34 years 0.99 (0.73, 1.33) .9413 0.53 (0.47, 0.59) 0.93 (0.78, 1.12) .4611– b.0001
35 39 years 0.97 (0.69, 1.37) .8731 0.49 (0.43, 0.56) 0.81 (0.66, 1.00) .0545– b.0001
40 44 years 1.00 (0.66, 1.53) .9871 0.42 (0.36, 0.50) 1.09 (0.86, 1.40) .4776– b.0001
45 49 years 1.04 (0.53, 2.05) .9126 0.47 (0.35, 0.63) 0.86 (0.56, 1.33) .5033– b.0001
Race
White (reference)
African American 0.41 (0.31, 0.55) 0.74 (0.67, 0.81) 0.72 (0.62, 0.84)b.0001 b.0001 b.0001
Hispanic 0.46 (0.31, 0.69) 1.01 (0.89, 1.15) .8999 0.66 (0.53, 0.82).0002 .0001
Other Race 0.36 (0.13, 0.98) 0.56 (0.41, 0.77) 0.61 (0.37, 0.99).0449 .0004 .0463
Unknown 0.78 (0.45, 1.36) .3792 0.96 (0.77, 1.19) .7133 0.79 (0.56, 1.13) .1961
Geographic region
Northeast (ref)
 
 
South 1.26 (0.97,1.66) .0895 0.98 (0.87, 1.09) .6533 0.90 (0.77, 1.06) .2158
Midwest 0.88 (0.67,1.17) .3849 0.98 (0.88, 1.09) .6879 0.84 (0.71, 0.98) .0291
West 1.25 (0.80,1.94) .3219 1.25 (1.04, 1.51) 1.13 (0.86, 1.49) .3888.0178
Unknown 2.12 (1.34, 3.34) 1.23 (0.98, 1.53) .0717 0.93 (0.66, 1.31) .6823.0013
CCI score
0 (ref)
≥1 1.31 (0.93, 1.85) .1291 1.31 (1.12, 1.53) 1.24 (0.99, 1.56) .0615.0008
Comorbidity
Hypertension 1.16 (0.84, 1.60) .3769 1.21 (1.05, 1.38) 1.20 (0.99, 1.46) .0702.0064
Asthma 0.95 (0.61, 1.47) .8141 1.14 (0.94, 1.38) .1901 1.01 (0.76, 1.33) .9744
Hypothyroidism 0.81 (0.48, 1.35) .4113 1.13 (0.93, 1.39) .2244 1.22 (0.92, 1.62) .1705
Diabetes 0.90 (0.53, 1.52) .6939 1.04 (0.83, 1.31) .7124 1.09 (0.79, 1.49) .6133
Obesity 0.65 (0.40, 1.06) .0871 1.16 (0.98, 1.36) .0841 1.28 (1.02, 1.62) .0373
Pelvic pain-related conditions
 
 
Fibroid 1.65 (0.86, 3.15) .1309 1.09 (0.79, 1.52) .6023 1.38 (0.90, 2.11) .1375
Benign ovarian neoplasms 2.33 (1.70, 3.19) 2.06 (1.72, 2.47) 1.19 (0.92, 1.53) .1881b.0001 b.0001
Baseline pain 1.95 (1.60, 2.37) 2.59 (2.40, 2.80)b.0001 b b.0001 1.66 (1.48, 1.87) .0001
Baseline AUB 2.03 (1.55, 2.66) 1.40 (1.22, 1.62) 2.21 (1.86, 2.64)b.0001 b.0001 b.0001
Prior pregnancy or delivery a  
 
0.94 (0.77, 1.15) .5465 0.87 (0.80, 0.94) 0.99 (0.87, 1.11) .8114.0005
Prior contraceptive use b
Oral contracepti ves 0.99 (0.67, 1.47) .9507 1.08 (0.92, 1.26) .3408 1.15 (0.92, 1.45) .2262
Injectable contraceptives 1.25 (0.94, 1.67) .1202 1.11 (0.99, 1.25) .0724 1.30 (1.10, 1.54) .0025
 
 
Note: Values in italics indicate those meeting the criteria for statistical signi cance (p value).fi
a Six weeks or more before index date.
b Within the 6 months prior to the index date.
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agnoses were based solely on ICD-9 or CPT c odes. Operationalization of
concepts, such as CPP and AUB, must rely on the frequency of the codes
reported as clinical records are not avai lable. In addition, other variables,
such as level of education and socioeconomic status, are known to affect
reports of chronic pelvic pain, AUB and hysterectomy [15]. It is unknown
how unmeasured varia bles such as these would affect these analyses.
diagnosis of CPP at 12 and 24 months, but not 6 m onths, a fter steriliza-
tion compared to TL. The clinical relevance of these ndings is uncertainfi
given the small absolute difference in rates. The incidence rates of AUB
at 6, 12 and 24 months poststerilization were similar in women who
 
 
 
 
underwent HS compared to TL ( ). Logistic regression analysesTable 3
support these findings.
Supplementary data to this article can be found online at http s:// doi.
org/10.1016/j.contraception.2017.12.015.
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